SecSonar.com

Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Zevra Therapeutics, Inc. (ZVRA) is a Biotechnology company based in US with a market capitalization of $684.8M. Revenue grew 350.9% year-over-year and free cash flow was negative at -$2.4M. This page tracks ZVRA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 59 employees · IPO Apr 16, 2015

Valuation

Valuation & price

$11.01 · as of May 17, 2026 · -23.2% vs 52w high

7.6

P/E ratio

Latest-FY diluted EPS

4.43

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$13.98$10.62$7.26Jul 25Dec 25Jul 26Jul 7, 25$11.27Jul 9, 25$11.56Jul 11, 25$12.53Jul 15, 25$12.79Jul 17, 25$12.66Jul 21, 25$11.73Jul 23, 25$11.77Jul 25, 25$11.23Jul 29, 25$10.81Jul 31, 25$11.11Aug 4, 25$11.25Aug 6, 25$11.48Aug 11, 25$11.70Aug 13, 25$9.43Aug 15, 25$9.43Aug 19, 25$9.01Aug 21, 25$9.51Aug 25, 25$9.36Aug 27, 25$9.36Aug 29, 25$9.07Sep 3, 25$8.92Sep 5, 25$8.95Sep 9, 25$8.21Sep 11, 25$7.95Sep 16, 25$7.26Sep 18, 25$7.94Sep 22, 25$7.95Sep 24, 25$8.95Sep 26, 25$9.77Sep 30, 25$9.51Oct 2, 25$9.31Oct 6, 25$10.65Oct 8, 25$10.64Oct 10, 25$11.01Oct 14, 25$10.49Oct 16, 25$11.38Oct 21, 25$11.10Oct 23, 25$10.68Oct 27, 25$11.08Oct 29, 25$10.12Oct 31, 25$10.18Nov 4, 25$9.79Nov 6, 25$9.09Nov 10, 25$9.10Nov 12, 25$9.40Nov 14, 25$8.88Nov 18, 25$9.70Nov 20, 25$9.05Nov 25, 25$8.40Nov 28, 25$8.43Dec 2, 25$8.17Dec 4, 25$8.66Dec 8, 25$8.78Dec 10, 25$8.45Dec 12, 25$8.33Dec 16, 25$8.12Dec 18, 25$8.10Dec 22, 25$8.55Dec 24, 25$8.64Dec 29, 25$8.82Jan 2, 26$8.34Jan 6, 26$8.31Jan 8, 26$8.63Jan 12, 26$8.38Jan 14, 26$9.17Jan 16, 26$8.93Jan 21, 26$9.03Jan 23, 26$8.97Jan 27, 26$8.93Jan 29, 26$8.86Feb 2, 26$9.36Feb 4, 26$8.94Feb 9, 26$8.57Feb 11, 26$8.48Feb 13, 26$8.50Feb 18, 26$8.65Feb 20, 26$8.80Feb 24, 26$8.97Feb 26, 26$9.09Mar 2, 26$9.09Mar 4, 26$8.93Mar 6, 26$8.98Mar 10, 26$11.06Mar 12, 26$10.19Mar 17, 26$9.90Mar 19, 26$9.40Mar 23, 26$9.42Mar 25, 26$9.13Mar 27, 26$9.16Mar 31, 26$9.32Apr 2, 26$9.40Apr 7, 26$9.68Apr 9, 26$9.71Apr 13, 26$9.72Apr 15, 26$10.32Apr 17, 26$10.67Apr 22, 26$10.49Apr 24, 26$10.08Apr 28, 26$9.90Apr 30, 26$10.17May 4, 26$10.05May 6, 26$11.25May 8, 26$11.13May 12, 26$11.05May 14, 26$11.66May 18, 26$10.43May 20, 26$10.24May 22, 26$10.03May 28, 26$11.40Jun 1, 26$11.49Jun 3, 26$10.96Jun 5, 26$10.61Jun 9, 26$13.66Jun 11, 26$12.97Jun 15, 26$12.55Jun 17, 26$12.61Jun 22, 26$12.65Jun 24, 26$13.08Jun 26, 26$13.52Jul 2, 26$13.98
$7.2352-week range$14.34
Loading valuation history…

Fundamentals

Key fundamentals

$684.8M

Market cap

350.9%

Revenue growth (YoY)

84.5%

Gross margin

-$2.4M

Free cash flow (USD)

-$127.8M

Net debt

Net cash position

19.6%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$12.8MFY 2020$13.3MFY 2021$28.6MFY 2022$10.2MFY 2023$27.5MFY 2024$23.6MFY 2025$106.5M
$0$106.5M

Free cash flow by year

2016 → 2025

FY 2016$-30.4MFY 2017$-33.3MFY 2018$-54.2MFY 2019$-23.8MFY 2020$-2.0MFY 2021$10.3MFY 2022$-18.8MFY 2023$-33.8MFY 2024$-69.7MFY 2025$-2.4M
-$30.4M-$2.4M

Gross margin by year

2021 → 2025

FY 202192.8%FY 202297.8%FY 202389.3%FY 202468.6%FY 202584.5%
92.8%84.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $438K · 10b5-1 PlanThompson Rahsaan · Chief Legal & Compliance · $438.3KJun 23, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 5, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing

Questions

Frequently asked questions

What is Zevra Therapeutics, Inc.'s market cap?

Zevra Therapeutics, Inc. (ZVRA) has a market capitalization of $684.8M.

What is ZVRA's P/E ratio?

ZVRA trades at a price-to-earnings ratio of 7.6, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is ZVRA's price-to-book (P/B) ratio?

ZVRA trades at 4.43 times book value per share.

Are insiders buying ZVRA stock?

SEC Form 4 filings show no open-market insider buys at Zevra Therapeutics, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

CRMD

CorMedix Inc.

$659.8M

ANL

Adlai Nortye Ltd.

$652.4M

ESPR

Esperion Therapeutics, Inc.

$650.8M

BIOA

BioAge Labs, Inc.

$646.1M

PRME

Prime Medicine, Inc.

$632.2M

DNA

Ginkgo Bioworks Holdings, Inc.

$628.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.